Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 1-2, 2007, Pages 102-105

  Zand, Negin ^a   Tajik, Nader ^a   Moghaddam, Alireza Salek ^a   Milanian, Iraj ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CYP2C19; CYP2C9; Iranian population; Pharmacogenetics; Polymerase chain reaction restriction fragment length polymorphism; Polymorphism

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DATA ANALYSIS; ENZYME ASSAY; ENZYME METABOLISM; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IRAN; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IRAN; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC;

EID: 33846069184     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04538.x     Document Type: Article

References (22)

1. van WJ, Steijns LS. Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology. Ann. Clin. Biochem. 1999; 36: 722-9.
2. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res. 2004; 50: 195-200.
3. Miners JO, Birkett DJ. Cytochrome P450 2C9: An enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 1998; 45: 525-38.
4. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol. 2001; 52: 447-50.
5. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7: 405-9.
6. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: Ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 2002; 54: 1257-70.
7. Nakamura K, Goto F, Ray WA et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 1985; 38: 402-8.
8. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 1994; 269: 15 419-22.
9. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-63.
10. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 1994; 46: 594-8.
11. Brosen K, De Morais SM, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Pharmacogenetics 1995; 5: 312-17.
12. Blaisdell J, Mohrenweiser H, Jackson J et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 2002; 12: 703-11.
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16: 1215.
14. Wang SL, Huang J, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37-42.
15. Goldstein JA, Ishizaki T, Chiba K et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7: 59-64.
16. Scordo MG. Cytochrome P450 2C9, 2C19 and 2D6 genetic polymorphisms evaluation of genotyping as a tool for individualised treatment. PhD Thesis, Karolinska Institue at Huddinge University Hospital, Stockholm, Sweden. 2003.
17. Peyvandi F, Spreafico M, Karimi M, Zeinali S, Mannucci PM, Bianchi Bonomi A. Allele frequency of CYP2C9 gene polymorphisms in Iran. Thromb. Haemost. 2002; 88: 874-5.
18. Ozawa S, Soyama A, Saeki M et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. 2004; 19: 83-95.
19. Ruas JL, Lechner MC. Allele frequency of CYP2C19 in a Portuguese population. Pharmacogenetics 1997; 7: 333-5.
20. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W (ed.). Pharmacogenetics of Drug Metabolism. Pergamon Press, New York. 1992; 657-85.
21. Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J. 2006; 6: 16-21.
22. Kalow W. Pharmacogenetics and pharmacogenomics: Origin, status, and the hope for personalized medicine. Pharmacogenomics J. 2006; 162-5.